Lustgarten Foundation Appoints Arthur Kuan, MS, to Board of Directors

Strategic Insights -

The Lustgarten Foundation, the world's largest private funder of pancreatic cancer research, has announced the appointment of Arthur Kuan, MS, to its Board of Directors. Kuan brings a unique blend of biotechnology innovation and clinical development expertise to the board, having led clinical-stage biotechnology company CG Oncology as its CEO since 2016. Under his leadership, the company has advanced a lead oncolytic immunotherapy candidate for bladder cancer through seven clinical programs, including two phase 3 trials. Kuan's appointment to the Lustgarten Foundation Board of Directors is seen as a significant boost to the organization's efforts to advance pancreatic cancer research and bring innovative treatment options to patients.

Key Takeaways:

  • Arthur Kuan, MS, joins the Lustgarten Foundation Board of Directors as Chairman and CEO of CG Oncology, a clinical-stage biotechnology company pioneering oncolytic immunotherapies for patients with urologic cancers.
  • Kuan brings extensive experience in biotechnology company building, venture capital, and immuno-oncology innovation, having led CG Oncology's strategy, clinical programs, and partnerships since 2016.
  • Under Kuan's leadership, CG Oncology has advanced cretostimogene, its lead oncolytic immunotherapy candidate for bladder cancer, through seven clinical programs, including two phase 3 trials.
  • Kuan's passion for advancing cancer research is deeply personal, having lost his father to pancreatic cancer at the age of 52.
  • Pancreatic cancer represents only 3% of all cancers diagnosed in the United States each year, yet it is the third-leading cause of cancer-related deaths and is poised to become the second by 2030.
  • The five-year survival rate for all stages of pancreatic cancer has reached an unprecedented high of 13%, thanks in part to the work of the Lustgarten Foundation.
  • The Lustgarten Foundation has played a driving role in every major advancement in pancreatic cancer research, guiding bold and innovative studies with the support of its esteemed Board of Directors.
  • Kuan's appointment to the Lustgarten Foundation Board of Directors is seen as a significant boost to the organization's efforts to advance pancreatic cancer research and bring innovative treatment options to patients.

Statistics:

  • 3% of all cancers diagnosed in the United States each year are pancreatic cancer.
  • Pancreatic cancer is the third-leading cause of cancer-related deaths in the United States.
  • By 2030, pancreatic cancer is poised to become the second leading cause of cancer-related deaths.
  • The five-year survival rate for all stages of pancreatic cancer has reached an unprecedented high of 13%.
  • The Lustgarten Foundation is the world's largest private funder of pancreatic cancer research.

Sources:

  • "Arthur Kuan Joins Lustgarten Foundation Board of Directors" (PRNewswire-PRWeb, July 1, 2025)
  • "Lustgarten Foundation Announces Appointment of Arthur Kuan, MS, to Board of Directors" (Lustgarten Foundation, July 1, 2025)